Accurate Clinical Management — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$16,986	2
2022	Research	$28,070	11
2021	Research	$29,342	2
2019	Research	$46,177	11

Breakdown

Who paid Research payments · program years 2019–2025

Biogen, Inc. $38,788 2 payments
Amgen Inc. $31,521 4 payments
AbbVie, Inc. $28,055 10 payments
Ucb SA $15,757 6 payments
Shionogi Inc $6,454 4 payments

Studies the money was for Research payments · program years 2019–2025

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) $28,055 10 payments
Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) $23,966 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care. $14,822 1 payment
Ph2b In Subjects with SLE $14,520 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $11,139 1 payment
A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $8,392 3 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $7,366 3 payments
Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2 $6,454 4 payments
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) $5,847 1 payment
P2b SLE $15 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.